Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

Rhea-AI Summary

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announces participation in two investor conferences with Chairman and CEO Leonard Mazur presenting at BIO CEO and Investor Conference and Sidoti Small-Cap Virtual Conference. Details of the presentations and registration information provided.

CRANFORD, N.J., Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences. Citius Chairman and CEO Leonard Mazur will present at the BIO CEO and Investor Conference on February 26-27, 2024, and the Sidoti Small-Cap Virtual Conference on March 13-14, 2024.

BIO CEO and Investor Conference Details:

Presentation:	9:45 am ET on Tuesday, February 27, 2024
Location:	New York Marriott Marquis, New York City
Registration:	Available on the conference website.

Sidoti Small-Cap Virtual Conference Details:

Presentation:	1:45 pm ET on Wednesday, March 13, 2024
Location:	Virtual
Registration:	Available on the conference website.
1x1 meetings:	Requests available through a Sidoti representative

About Citius Pharmaceuticals, Inc.

Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. At the end of 2023, Citius completed enrollment in a Phase 3 Pivotal superiority trial of Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. Citius has recently resubmitted the Biologics License Application for LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-upcoming-bio-ceo-and-sidoti-investor-conferences-302069457.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When will Citius Pharmaceuticals participate in the BIO CEO and Investor Conference?

Citius Pharmaceuticals will participate in the BIO CEO and Investor Conference on February 26-27, 2024.

Where will Leonard Mazur present at the BIO CEO and Investor Conference?

Leonard Mazur will present at the New York Marriott Marquis, New York City.

What is the date and time of the presentation at the Sidoti Small-Cap Virtual Conference?

The presentation at the Sidoti Small-Cap Virtual Conference will be on March 13, 2024, at 1:45 pm ET.

How can one register for the BIO CEO and Investor Conference?

Registration is available on the conference website.

Are 1x1 meetings available at the Sidoti Small-Cap Virtual Conference?

Requests for 1x1 meetings are available through a Sidoti representative.